Peptide Antibiotics
Polymyxins, Glycopeptides, Bacitracin, and Fosfomycin
Patricia M. Dowling
Search for more papers by this authorPatricia M. Dowling
Search for more papers by this authorSteeve Giguère DVM, PhD, DACVIM
Professor, Large Animal Internal Medicine
Marguerite Hodgson Chair in Equine Studies, College of Veterinary Medicine, University of Georgia
Search for more papers by this authorJohn F. Prescott MA, VetMB, PhD
Professor
Department of Pathobiology, University of Guelph
Search for more papers by this authorPatricia M. Dowling DVM, MS, DACVIM, DACVCP
Professor, Veterinary Clinical Pharmacology
Veterinary Biomedical Sciences, University of Saskatchewan
Search for more papers by this authorSummary
This chapter discusses the chemistry, mechanism of action, antimicrobial activity, resistance, pharmacokinetic properties, drug interactions, toxicity and adverse effects, administration, dosage and clinical applications of peptide antibiotics. Peptide antibiotics include polymyxins, glycopeptides, bacitracin, and fosfomycin with a variety of actions against bacteria. Polymyxin B and colistin are similarly rapidly bactericidal and highly active against many species of gram-negative organisms, such as Escherichia coli, Salmonella, and Pseudomonas aeruginosa, but not against Proteus, Serratia, or Providencia. Glycopeptides antibiotics show activity against gram-positive bacteria and particularly against gram-positive cocci. Bacitracin is a polypeptide product of Bacillus subtilis. It is bactericidal to gram-positive bacteria but has little activity against gram-negative organisms. Fosfomycin has a broad spectrum of activity against a wide range of gram-positive and gram-negative bacteria. It is highly active against gram-positive pathogens such as Staphylococcus aureus and Enterococcus, and against gram-negative bacteria such as P. aeruginosa and Klebsiella pneumonia.
Bibliography
- Barton MH, et al. 2004. Polymyxin B protects horses against induced endotoxaemia in vivo. Equine Vet J 36: 397.
- Coyne CP, et al. 1993. Inhibition of lipopolysaccharide-induced macrophage tumor necrosis factor-alpha synthesis by polymyxin B sulfate. Am J Vet Res 54: 305.
- Durando MM, et al. 1994. Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am J Vet Res 55: 921.
- Falagas ME, et al. 2010. Resistance to polymyxins: Mechanisms, frequency and treatment options. Drug Resist Updat 13: 132.
- Giamarellos-Bourboulis EJ, et al. 2003. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 15: 235.
- Guyonnet J, et al. 2010. Determination of a dosage regimen of colistin by pharmacokinetic/pharmacodynamic integration and modeling for treatment of G.I.T. disease in pigs. Res Vet Sci 88: 307.
- Hariharan H, et al. 2006. Update on antimicrobial susceptibilities of bacterial isolates from canine and feline otitis externa. Can Vet J 47: 253.
- Hume-Smith KM, et al. 2011. Anaphylactic events observed within 4 h of ocular application of an antibiotic-containing ophthalmic preparation: 61 cats (1993–2010). J Feline Med Surg 13: 744.
- Lim LM, et al. 2010. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30: 1279.
- Lin B, et al. 2005. Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. J Vet Pharmacol Ther 28: 349.
- Morresey PR, et al. 2006. Endotoxin-neutralizing activity of polymyxin B in blood after IV administration in horses. Am J Vet Res 67: 642.
- Raisbeck MF, et al. 1989. Effects of polymyxin B on selected features of equine carbohydrate overload. Vet Hum Toxicol 31: 422.
- Rybnicek J, et al. 2007. Suspected polymyxin B-induced pemphigus vulgaris in a dog. Vet Dermatol 18: 165.
- Senturk S. 2005. Evaluation of the anti-endotoxic effects of polymyxin-E (colistin) in dogs with naturally occurred endotoxic shock. J Vet Pharmacol Ther 28: 57.
- Sharp CR, et al. 2010. Evaluation of the anti-endotoxin effects of polymyxin B in a feline model of endotoxemia. J Feline Med Surg 12: 278.
- Tam VH, et al. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49: 3624.
- Yahav D, et al. 2012. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 18: 18.
- Zeng Z, et al. 2010. Study of colistin depletion in duck tissues after intramuscular and oral administration. J Vet Pharmacol Ther 33: 408.
- Ziv G. 1981. Clinical pharmacology of polymyxins. J Am Vet Med Assoc 179: 711.
- Ziv G, et al. 1982. The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves. J Vet Pharmacol Ther 5: 45.
- Ziv G, et al. 1983. Influence of intramammary infusion of polymyxin B on the clinicopathologic course of endotoxin-induced mastitis. Am J Vet Res 44: 1446.
- Bibliography
- Aarestrup FM, et al. 2001. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob Agents Chemother 45: 2054.
- Atilla A, et al. 2010. In vitro elution of amikacin and vancomycin from impregnated plaster of Paris beads. Vet Surg 39: 715.
- Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17: 479.
- Freitas AR, et al. 2011. Human and swine hosts share vancomycin-resistant Enterococcus faecium CC17 and CC5 and Enterococcus faecalis CC2 clonal clusters harboring Tn1546 on indistinguishable plasmids. J Clin Microbiol 49: 925.
- Ghosh A, et al. 2011. Dogs leaving the ICU carry a very large multi-drug resistant enterococcal population with capacity for biofilm formation and horizontal gene transfer. PLoS One 6: e22451.
- Ghosh A, et al. 2012. Resident cats in small animal veterinary hospitals carry multi-drug resistant enterococci and are likely involved in cross-contamination of the hospital environment. Front Microbiol 3: 62.
- Jackson MW, et al. 1994. Administration of vancomycin for treatment of ascending bacterial cholangiohepatitis in a cat. J Am Vet Med Assoc 204: 602.
- Johnsen PJ, et al. 2011. Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures. J Antimicrob Chemother 66: 608.
- Joosten U, et al. 2005. Effectiveness of hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus aureus induced chronic osteomyelitis. Biomaterials 26: 5251.
- Liu SJ, et al. 2002. In vivo release of vancomycin from biodegradable beads. J Biomed Mater Res 63: 807.
- Orsini JA, et al. 1992. Vancomycin kinetics in plasma and synovial fluid following intravenous administration in horses. J Vet Pharmacol Ther 15: 351.
- Orsini JA, et al. 2005. Vancomycin for the treatment of methicillin-resistant staphylococcal and enterococcal infections in 15 horses. Can J Vet Res 69: 278.
- Pressel MA, et al. 2005. Vancomycin for multi-drug resistant Enterococcus faecium cholangiohepatitis in a cat. J Feline Med Surg 7: 317.
- Ramos S, et al. 2012. Genetic characterisation of antibiotic resistance and virulence factors in vanA-containing enterococci from cattle, sheep and pigs subsequent to the discontinuation of the use of avoparcin. Vet J 193: 301.
- Rubio-Martinez L, et al. 2005. Medullary plasma pharmacokinetics of vancomycin after intravenous and intraosseous perfusion of the proximal phalanx in horses. Vet Surg 34: 618.
- Rubio-Martinez LM, et al. 2005. Evaluation of safety and pharmacokinetics of vancomycin after intravenous regional limb perfusion in horses. Am J Vet Res 66: 2107.
- Thomas LA, et al. 2011. In vitro elution and antibacterial activity of clindamycin, amikacin, and vancomycin from R-gel polymer. Vet Surg 40: 774.
- Trostle SS, et al. 2001. Treatment of methicillin-resistant Staphylococcus epidermidis infection following repair of an ulnar fracture and humeroradial joint luxation in a horse. J Am Vet Med Assoc 218: 554.
- Weese JS. 2008. Issues regarding the use of vancomycin in companion animals. J Am Vet Med Assoc 233: 565.
- Witte W. 2004. Glycopeptide resistant Staphylococcus. J Vet Med B Infect Dis Vet Public Health 51: 370.
- Zaghlol HA, et al. 1988. Single- and multiple-dose pharmacokinetics of intravenously administered vancomycin in dogs. Am J Vet Res 49: 1637.
- Bibliography
- Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17: 479.
- Gomez A, et al. 1995. An encrusted cystitis caused by Corynebacterium urealyticum in a dog. Aust Vet J 72: 72.
- Naccari C, et al. 2009. Pharmacokinetics and efficacy of teicoplanin against intramammary infections in sheep. Vet Rec 165: 19.
- Bibliography
- Aarestrup FM, et al. 2001. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob Agents Chemother 45: 2054.
- Casewell M, et al. 2003. The European ban on growth-promoting antibiotics and emerging consequences for human and animal health. J Antimicrob Chemother 52: 159.
- Kuhn I, et al. 2005. Occurrence and relatedness of vancomycin-resistant enterococci in animals, humans, and the environment in different European regions. Appl Environ Microbiol 71: 5383.
- Bibliography
- Butaye P, et al. 2003. Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria. Clin Microbiol Rev 16: 175.
- Castanon JI. 2007. History of the use of antibiotic as growth promoters in European poultry feeds. Poult Sci 86: 2466.
- Jacob SE, et al. 2004. From road rash to top allergen in a flash: bacitracin. Dermatol Surg 30: 521.
- Keir AA, et al. 1999. Outbreak of acute colitis on a horse farm associated with tetracycline-contaminated sweet feed. Can Vet J 40: 718.
- Keller RL, et al. 2005. Bacterial isolates and antimicrobial susceptibilities in equine bacterial ulcerative keratitis (1993–2004). Equine Vet J 37: 207.
- Kyriakis SC, et al. 1996. Clinical evaluation of in-feed zinc bacitracin for the control of porcine intestinal adenomatosis in growing/fattening pigs. Vet Rec 138: 489.
- Bibliography
- Falagas ME, et al. 2010b. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 10: 43.
- Fernandez A, et al. 1998. Efficacy of phosphomycin in the control of Escherichia coli infection of broiler chickens. Res Vet Sci 65: 201.
- Fukata T, et al. 2008. Acute renal insufficiency in cats after fosfomycin administration. Vet Rec 163: 337.
- Gutierrez L, et al. 2010. Pharmacokinetics of disodium fosfomycin in broilers and dose strategies to comply with its pharmacodynamics versus Escherichia coli. Poult Sci 89: 2106.
- Gutierrez OL, et al. 2008. Pharmacokinetics of disodium-fosfomycin in mongrel dogs. Res Vet Sci 85: 156.
- Hubka P, et al. 2011. In vitro susceptibility of canine and feline Escherichia coli to fosfomycin. Vet Microbiol 149: 277.
- Michalopoulos AS, et al. 2011. The revival of fosfomycin. Int J Infect Dis 15: e732.
- Soraci AL, et al. 2011. Disodium-fosfomycin pharmacokinetics and bioavailability in post weaning piglets. Res Vet Sci 90: 498.
- Sumano LH, et al. 2007. Intravenous and intramuscular pharmacokinetics of a single-daily dose of disodium-fosfomycin in cattle, administered for 3 days. J Vet Pharmacol Ther 30: 49.
- Zozaya DH, et al. 2008. Pharmacokinetics of a single bolus intravenous, intramuscular and subcutaneous dose of disodium fosfomycin in horses. J Vet Pharmacol Ther 31: 321.